Drug-Eluting Stents Will Be Model For CMS/FDA Cooperation – McClellan

The drug-eluting stent approval and reimbursement process should serve as a model for how CMS and FDA can work more closely together to ensure coverage for new technologies, CMS Administrator Mark McClellan told the Food & Drug Law Institute conference in Washington, D.C. April 15